Skip to content
CompletedPhase 4Results posted

NMDA Antagonists in Bipolar Depression

NCT01833897 · New York State Psychiatric Institute

Closed to entry
Status
Not accepting participants
Phase 4
Phase
8
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

The purpose of this study is to test whether ketamine and D-cycloserine can be safely and effectively used for the treatment of depression. The investigators hypothesize that ketamine will serve as a rapid acting and safe antidepressant in patients with bipolar depression, and furthermore, that D-cycloserine will serve as an effective therapy following ketamine treatment.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Hamilton Depression Rating Scale (HAM-D)

    Measured over 8 weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 60 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Male and female patients with Diagnostic and Statistical Manual, Version 4 (DSM-IV) diagnosis of bipolar disorder I or II, current major depressive episode without psychotic features, 18-60 * Insufficient therapeutic response during the current episode * Medically stable for study participation * Judged clinically not to be at significant suicide or violence risk * Subject is off all psychotropic and other types of drugs likely to interact with glutamate for at least 14 days before starting the study. One exception is chloral hydrate or short acting benzodiazepines for distressing anxiety or insomnia (up to 72 hours prior to each MRI scan). In addition, subjects will be off antipsychotics for 1 month and off fluoxetine for 6 weeks prior to the study. * Subject is likely to be able to tolerate a medication washout. Only subjects who have failed their current medication regiment will be washed off medications. Exclusion Criteria: * History of chronic psychosis or drug induced psychosis of any kind * Current DSM-IV diagnosis of drug abuse/dependence in the last six months. Subjects must have a negative drug screen at baseline. * Women will be excluded if they are pregnant lactating, or not either surgically-sterile or using appropriate methods of birth control. Women must agree to continue using applicable birth control throughout the trial. All women of child-bearing potential must have a negative urine pregnancy test * Taking any medication contraindicated with ketamine or DCS (ethionamide, isoniazid) * History of seizures, renal insufficiency or congestive heart failure * History of clinically significant violence * History of ketamine abuse/dependence or prior clinically significant adverse reaction to ketamine * Current alcohol abuse or dependence * Untreated hypertension * Clinically abnormal liver function tests (LFTs), thyroid, renal function or anemia * Metal implants, pacemaker, other metal (e.g. shrapnel or surgical prostheses) or paramagnetic objects contained within the body which may present a risk to the subject or interfere with the MR scan. * Medicinal patch, unless removed prior to the MR scan

Where

1 study site

FacilityCityRegionCountry
New York State Psychiatric InstituteNew YorkNew YorkUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT01833897 on ClinicalTrials.gov →

Last updated in the registry 2016-06-01. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits